Can persistent erythrocytosis worsen headache, dizziness, or cognitive symptoms?

Persistent erythrocytosis is a clinically credible contributor to neurologic and cognitive-type symptoms, particularly when hematocrit is substantially elevated or symptoms occur in a setting such as polycythemia vera or hypoxic lung disease.

Clinical and physiologic evidence

• Hematocrit is a major determinant of whole-blood viscosity. Viscosity rises nonlinearly as red-cell fraction increases, especially under low-shear microcirculatory conditions; reducing hematocrit in polycythemic states correspondingly lowers viscosity.
• Higher viscosity can raise cerebrovascular resistance and reduce cerebral blood flow. In COPD-associated polycythemia, reducing hematocrit from 59.6% to 43.9% reduced viscosity by 35% and increased supratentorial cerebral flow by 78%. In polycythemia vera, hematocrit reduction toward 45.5% was associated with a reported 73% improvement in cerebral flow.
• Headache, dizziness/vertigo, visual phenomena, paresthesias, and impaired concentration are recognized in polycythemia vera and are consistent with hyperviscosity and microvascular-flow disturbance. In hypoxic lung disease with hematocrit >54%, 8/11 phlebotomized participants reported improvement in headache, fatigue, or dyspnea; benefit was greater above 60%. In hereditary erythrocytosis, 9/17 patients reported improvement in headache, dizziness, tinnitus, or visual symptoms after phlebotomy.

Mechanistic interpretation

• Increased red-cell concentration impairs flow through small vessels and may reduce cerebrovascular reactivity. Endothelial dysfunction and microvascular ischemia offer additional pathways for neurologic symptoms.
• Reduced cerebral perfusion is associated with cognitive impairment, but direct evidence that erythrocytosis-mediated hypoperfusion causes objectively measured cognitive decline remains less direct. Confusion should therefore not be presumed due to hematocrit alone.

Clinical implications

• In polycythemia vera, hematocrit control below 45% reduces thrombotic/cardiovascular risk. In secondary erythrocytosis, treatment should target causes such as hypoxia, dehydration, or iron deficiency rather than routine phlebotomy.
• Bottom line: Persistent erythrocytosis can worsen headache, dizziness, and concentration-related symptoms through hyperviscosity and reduced cerebral flow; acute confusion or focal neurologic symptoms require urgent evaluation for stroke or other causes.